Literature DB >> 22687664

Metyrapone: a management option for ectopic ACTH syndrome in small cell lung cancer treated with intravenous etoposide.

Shaikh Irfan Aziz1, Muhammad Adnan Khattak, Zafar Usmani, Narsing Ladipeerla, Ken Pittman.   

Abstract

Small cell lung cancer (SCLC) with ectopic adrenocorticotropic hormone (ACTH) syndrome and resultant hypercortisolism carries a poor prognosis with a short median survival and high incidence of infective complications. The combination of etoposide with either carboplatin or cisplatin is the current standard chemotherapy used for the management of SCLC. Etoposide is metabolised by cytochrome P450 3A4. Ketoconazole is an imidazole derivative possessing antifungal properties and also causes inhibition of adrenal corticosteroid and androgen production. There is an additional increased risk of toxicity due to a potential interaction between etoposide and ketoconazole, which is a strong inhibitor of cytochrome P450 3A4, and theoretically can lead to greater myelosuppression. Metyrapone can be a safe alternative in such settings.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22687664      PMCID： PMC4545102          DOI： 10.1136/bcr.04.2010.2917

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  8 in total

1.  A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes.

Authors:  T Kawashiro; K Yamashita; X J Zhao; E Koyama; M Tani; K Chiba; T Ishizaki
Journal:  J Pharmacol Exp Ther       Date:  1998-09       Impact factor: 4.030

2.  Ketoconazole. Use in the treatment of ectopic adrenocorticotropic hormone production and Cushing's syndrome in small-cell lung cancer.

Authors:  F A Shepherd; B Hoffert; W K Evans; G Emery; J Trachtenberg
Journal:  Arch Intern Med       Date:  1985-05

3.  Hormonal polypeptides and amine metabolites in small cell carcinoma of the lung, with special reference to stage and subtypes.

Authors:  M Hansen; H H Hansen; F R Hirsch; J Arends; J D Christensen; J M Christensen; L Hummer; C Kühl
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

4.  Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.

Authors:  Wei Peng Yong; Apurva A Desai; Federico Innocenti; Jacqueline Ramirez; Dale Shepard; Ken Kobayashi; Larry House; Gini F Fleming; Nicholas J Vogelzang; Richard L Schilsky; Mark J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  2007-02-17       Impact factor: 3.333

5.  Endocrine function in small cell undifferentiated carcinoma of the lung.

Authors:  P K Bondy; E D Gilby
Journal:  Cancer       Date:  1982-11-15       Impact factor: 6.860

6.  Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

Authors:  B L Lum; S Kaubisch; A M Yahanda; K M Adler; L Jew; M N Ehsan; N A Brophy; J Halsey; M P Gosland; B I Sikic
Journal:  J Clin Oncol       Date:  1992-10       Impact factor: 44.544

7.  Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications.

Authors:  L Delisle; M J Boyer; D Warr; D Killinger; D Payne; J L Yeoh; R Feld
Journal:  Arch Intern Med       Date:  1993-03-22

8.  Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer.

Authors:  F A Shepherd; J Laskey; W K Evans; P E Goss; E Johansen; F Khamsi
Journal:  J Clin Oncol       Date:  1992-01       Impact factor: 44.544
  8 in total
  3 in total

1.  Refractory postoperative Staphylococcus hominis bacteremia in a patient with an ACTH-producing pancreatic neuroendocrine neoplasm: a case report.

Authors:  Ryuta Muraki; Yoshifumi Morita; Kyota Tatsuta; Shinya Ida; Ryo Kitajima; Amane Hirotsu; Makoto Takeda; Hirotoshi Kikuchi; Yoshihiro Hiramatsu; Atsuko Fukazawa; Go Kuroda; Keisuke Kakizawa; Hiroya Takeuchi
Journal:  Surg Case Rep       Date:  2022-06-29

2.  Comparison of tumor related signaling pathways with known compounds to determine potential agents for lung adenocarcinoma.

Authors:  Song Xu; Renwang Liu; Yurong Da
Journal:  Thorac Cancer       Date:  2018-06-05       Impact factor: 3.500

3.  Beyond the Dual Paraneoplastic Syndromes of Small-Cell Lung Cancer with ADH and ACTH Secretion: A Case Report with Literature Review and Future Implications.

Authors:  Krishna Adit Agarwal; Myat Han Soe
Journal:  Case Rep Oncol Med       Date:  2018-10-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.